Feds Now See the Need for Funding Antivirals: TrialSite will Track the Spend Carefully

Feds Now See the Need for Funding Antivirals TrialSite will Track the Spend Carefully

After over a year of TrialSite reporting on the need for early-onset, antiviral-like care for COVID-19, now the U.S. government will launch a mini “moonshot” targeting antivirals necessary not only for viruses such as SARS-CoV-2 but for the inevitable new ones that will surface in the future. Powered by the same players—that is, the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) as well as the Biomedical Advanced Research and Development Authority (BARDA)—under the current Executive Branch administration, a new program under Dr. Anthony Fauci’s NIAID called the “Antiviral Program for Pandemics” will target the 90% of cases involving either asymptomatic to mild-to-moderate SARS-CoV-2 infection. But now with a focus on “sustainable platforms” to discover and develop antivirals, perhaps one of the key players in what’s been a total failure on the part of the federal research apparatus to address affordable repurposed antivirals (other than ensure Gilead could secure billions starting last May), Dr. Anthony Fauci was still able to get his customary quote, emphasizing, “New antivirals that prevent serious COVID-19 illness and dea...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee